Jean Jacques Bienaime - 18 Apr 2022 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
Chief Executive Officer, Director
Signature
/s/ Eric Fleekop, Attorney-in-Fact
Issuer symbol
BMRN
Transactions as of
18 Apr 2022
Net transactions value
-$889,000
Form type
4
Filing time
20 Apr 2022, 20:20:30 UTC
Previous filing
18 Apr 2022
Next filing
02 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Options Exercise $749,200 +20,000 +6% $37.46 354,983 18 Apr 2022 Direct F1
transaction BMRN Common Stock Sale $1,638,200 -20,000 -5.6% $81.91 334,983 18 Apr 2022 Direct F1
holding BMRN Common Stock 247,533 18 Apr 2022 Shares held by Jean-Jacques Bienaime Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -20,000 -27% $0.000000 55,000 18 Apr 2022 Common Stock 20,000 $37.46 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Trade made pursuant to a 10b5-1 plan executed on December 9, 2021, as amended on March 11, 2022. Mr. Bienaime's former spouse will receive approximately 60% of the net proceeds from the shares sold in this transaction pursuant to a marital separation agreement between her and Mr. Bienaime.
F2 Reflects the number of options outstanding after the transactions from this specific stock option grant.